Radiopharm Theranostics (ASX:RAD) has announced encouraging interim results from its U.S.-based Phase 2b clinical imaging trial of RAD 101, reporting that 92 per cent of evaluable patients achieved concordance between RAD 101 PET imaging and MRI, the study’s primary endpoint.
Radiopharm Theranostics reports high success rate in Phase 2b imaging trial
December 15, 2025 Australian Biotech
Latest Video
New Stories
-
Medicines Australia tells productivity inquiry PBS rules leave out economic benefits
November 16, 2026 - -
First official US count confirms the broad uptake of GLP-1s for weight management
November 16, 2026 - - Latest News -
Can the PBS afford another agreement on the same terms?
November 16, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 13 November
November 13, 2026 - - Podcast -
A year on, Sanofi now asks staff to explain how they used AI
November 13, 2026 - - Latest News -
There is no need for AI to automate the care out of healthcare, Cohn warns
November 13, 2026 - -
Cochlear's global government affairs chief is putting AI to work
November 13, 2026 - - Latest News

